Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Completes $400 Million IPO; Valuation is $2 Billion

publication date: Aug 1, 2018

Ascletis Pharma (HK: 1672) of Hangzhou completed a $400 million IPO on the Hong Kong exchange at a $2 billion capitalization. The company priced the offering at the mid-point of the proposed range and closed its first day of trading at the IPO price. Ascletis has developed a dual drug all-oral treatment for hepatitis C virus. The first of the two drugs will be launched in China next month. Yesterday, Ascletis said its NDA filing for the second candidate was accepted in China and will be reviewed under fast-track rules. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital